Welcome to our dedicated page for Arrivent Biopharma news (Ticker: AVBP), a resource for investors and traders seeking the latest updates and insights on Arrivent Biopharma stock.
ArriVent BioPharma, Inc. reports news as a clinical-stage biopharmaceutical company developing oncology therapeutics. Company updates center on firmonertinib, an EGFR inhibitor for EGFR mutant non-small cell lung cancer, including exon 20 insertion and PACC mutation settings, as well as regulatory designations, clinical data presentations, and global study activity.
Recurring developments also cover ArriVent's antibody-drug conjugate portfolio, including ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies, and ARR-002, a MUC16/NaPi2b targeting tetravalent ADC with an initial focus in ovarian and endometrial cancers. News releases also include IND clearances, oncology conference presentations, financial results, collaborations, and executive or commercial organization updates.
ArriVent BioPharma (Nasdaq: AVBP) reported Q2 2024 financial results and highlighted recent progress. Key points include:
1. Upcoming presentation of clinical proof-of-concept data for firmonertinib in EGFR PACC mutant NSCLC at WCLC 2024.
2. New ADC collaboration agreement with Alphamab, expanding ArriVent's oncology pipeline.
3. Financial position: $298.7 million in cash and cash equivalents, expected to fund operations into 2026.
4. R&D expenses increased to $38.8 million for H1 2024, up from $30.6 million in H1 2023.
5. Net loss of $39.3 million for H1 2024, compared to $33.7 million in H1 2023.
6. Anticipating top-line Phase 3 data for firmonertinib in NSCLC with EGFR exon 20 insertion mutations in 2025.
ArriVent BioPharma (Nasdaq: AVBP) will present interim randomized Phase 1b FURTHER data for first-line firmonertinib monotherapy in patients with non-small cell lung cancer (NSCLC) harboring EGFR PACC mutations at the 2024 World Conference on Lung Cancer (WCLC). The presentation, selected for the Presidential Symposium, marks the first prospectively designed randomized clinical data for a small-molecule EGFR tyrosine kinase inhibitor in this specific patient population. The study, titled 'FURTHER: A Global, Randomized study of Firmonertinib at Two Dose Levels in TKI-Naive, Advanced NSCLC with EGFR PACC Mutations,' will be presented on September 9, 2024. ArriVent will also host a virtual webinar on the firmonertinib program on the same day at 4:30pm ET.
ArriVent BioPharma has entered a collaboration with Jiangsu Alphamab Biopharmaceuticals to develop and commercialize novel antibody drug conjugates (ADCs) for cancer treatment. Under the agreement, ArriVent will utilize Alphamab's ADC research platform, while Alphamab will leverage ArriVent's global development expertise. The agreement includes potential milestone and upfront payments to Alphamab worth up to $615.5 million, excluding Greater China where Alphamab retains development and commercialization rights. Alphamab will also receive tiered sales royalties from ArriVent for each ADC product.
ArriVent BioPharma has appointed Dr. John Hohneker to its Board of Directors.
Dr. Hohneker brings over 30 years of biopharmaceutical leadership and drug development experience, previously holding key roles at Anokion SA, Forma Therapeutics, and Novartis AG.
He currently serves on the Boards of Carisma Therapeutics, Curis, Sonata Therapeutics, and Trishula Therapeutics.
Dr. Hohneker's expertise is expected to aid in advancing ArriVent's pipeline, including its lead candidate firmonertinib, aimed at addressing unmet cancer patient needs.
ArriVent BioPharma reported strong financial results for the first quarter of 2024, with a cash position of $317.4 million, showcasing positive progress in advancing their clinical programs. The company presented preclinical data on firmonertinib at the AACR Annual Meeting, demonstrating its effectiveness across a wide range of mutations in NSCLC. They also dosed the first patient in a Phase 1b combination study with ICP-189 for NSCLC patients with EGFR classical mutations. The company is on track to deliver proof-of-concept data in 2024 and is making strides in selecting a next-generation ADC development candidate.
Summary not available.
Summary not available.
Summary not available.